Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4

Cited by (352)

Items 201–300 of 352

1. Genetics and Epigenetics of the Skin Meet Deep Sequence
   Jeffrey B. Cheng, Raymond Jaihyun Cho · 2012 · Journal of Investigative Dermatology
2. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment
   Yuen‐Keng Ng, Jia-Ying Lloyd Lee, Kathryn M. Supko, Ayesha U. Khan, Salina M Torres, Marianne Berwick, Jonhan Ho, John M. Kirkwood, Jill M. Siegfried, Laura P. Stabile · 2014 · Melanoma Research
3. Beyond BRAF in Melanoma
   ADIL I. DAUD, Boris C. Bastian · 2010 · Current topics in microbiology and immunology
4. A Therapeutic Opportunity in Melanoma: ErbB4 Makes a Mark on Skin
   Jeff Settleman · 2009 · Cancer Cell
5. Melanoma genomics – will we go beyond BRAF in clinics?
   Justyna Mirek, Wiesław Bal, Magdalena Olbryt · 2024 · Journal of Cancer Research and Clinical Oncology
6. Near‐genomewide RNA i screening for regulators of BRAF V 600E ‐induced senescence identifies RASEF , a gene epigenetically silenced in melanoma
   Joanna Kaplon, Hömig-Hölzel Cornelia, Linda Y. Gao, Katrin Meissl, Els M.E. Verdegaal, Sjoerd H. van der Burg, Remco van Doorn, Daniel S. Peeper · 2014 · Pigment Cell & Melanoma Research
7. Afatinib-Based Combination Regimens for the Treatment of Solid Tumors: Rationale, Emerging Strategies and Recent Progress
   Jaafar Bennouna, Shanti Ricardo Moreno Vera · 2015 · Future Oncology
8. Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling
   Xiaowen Zhou, Bojia Liu, Qing Xiu Ning, Zhi Xia, Rongling Zhong, Li Zhang, Lei Wu · 2020 · Oncology Reports
9. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC
   Yu Nakamura, Yosuke Togashi, Hirokazu Nakahara, Shuta Tomida, Eri Banno, Masato Terashima, Hidetoshi Hayashi, Marco Antonio De Velasco, Kazuko Sakai, Yoshihiko Fujita et al. · 2016 · Molecular Cancer Therapeutics
10. Aloysia Citrodora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-EGFR Signaling
    Yousef Salama, Nidal Amin Jaradat, Koichi Hattori, Beate Heissig · 2021 · International Journal of Molecular Sciences
11. Nanoparticle-Based Combination Therapy for Melanoma
    Hongbo Chen, Kai Hou, Jing Yu, Le Wang, Xue Chen · 2022 · Frontiers in Oncology
12. Melanoma genetics: the other side
    Sabina Bis, Hensin Tsao · 2013 · Clinics in Dermatology
13. New Therapeutic Options in the Medical Management of Advanced Melanoma
    Jose Lutzky · 2010 · Seminars in Cutaneous Medicine and Surgery
14. Multistage Carcinogenesis
    Erika L. Abel, John DiGiovanni · 2010 · Humana Press eBooks
15. Lapatinib: new opportunities for management of breast cancer
    Joyce M. Slingerland, Lee, Gallas, Pegram, Joyce M. Slingerland · 2010 · Breast Cancer Targets and Therapy
16. Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling
    Sebastian Karl Wandinger, Idoya Lahortiga, Kris Jacobs, Martin Klammer, Nicole Jordan, Sarah Elschenbroich, Marc Paradé, Edgar Jacoby, Joannes T. M. Linders, Dirk Brehmer et al. · 2016 · PLoS ONE
17. Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model
    Anna E. Kersh, Maiko Sasaki, Lee Cooper, Haydn Thomas Kissick, Brian P. Pollack · 2016 · Frontiers in Pharmacology
18. New therapies in the treatment of melanoma
    Diwakar Davar, John M. Kirkwood · 2012 · Expert Opinion on Investigational Drugs
19. Orange is the new black: Kinases are the new master regulators of tumor suppression
    Elvira An, John Brognard · 2018 · IUBMB Life
20. MelanomaDB: A Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways
    Alexander J. Trevarton, Michael B. Mann, Christoph Knapp, Hiromitsu Araki, Jonathan D. Wren, Steven Stones-Havas, Michael A. Black, Cristin Gregor Print · 2013 · Frontiers in Oncology
21. Lack of genotoxicity due to foamy virus vector integration in human iPSCs
    David R. Deyle, Iram Khan, G Ren, D W Russell · 2013 · Gene Therapy
22. Mutational Signatures of De-Differentiation in Functional Non-Coding Regions of Melanoma Genomes
    Stephen C.J. Parker, Jared J. Gartner, Isabel Cárdenas-Navia, Xiaomu Wei, Hatice Özel Abaan, Subramanian S. Ajay, Nancy Fisher Hansen, Lingyun Song, Umesh Kumar Bhanot, J. Keith Killian et al. · 2012 · PLoS Genetics
23. Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy
    Doreen Manuela Floss, Jürgen Scheller · 2019 · Cytokine & Growth Factor Reviews
24. ErbB4 in the brain: Focus on high grade glioma
    Jamie-Lee Pitcher, Naomi Alexander, Panimaya Jeffreena Miranda, Terrance G. Johns · 2022 · Frontiers in Oncology
25. Clinical, Morphologic, and Genomic Differences in Deep-Penetrating Nevi and Deep-Penetrating Nevus-like Melanomas
    Lu Chen, Alice P. Chen, Natasha Sharma, Pragi Patel, Afua Konadu Addo, Julia Edwin Jeyakumar, Haya Mary Beydoun, Shantel Olivares, David Dittmann, Erica R Vormittag-Nocito et al. · 2025 · Modern Pathology
26. A population-based study of copy number variants and regions of homozygosity in healthy Swedish individuals
    Shu Mei Teo, Chee‐Seng Ku, Nasheen Naidoo, Per N Hall, Kee‐Seng Chia, Agus Salim, Yudi Pawitan Y · 2011 · Journal of Human Genetics
27. Whole Genome and Exome Sequencing of Melanoma
    Ken Dutton‐Regester, Nicholas K. Hayward · 2012 · Advances in pharmacology
28. Non-reproducible sequence artifacts in FFPE tissue: an experience report
    Richard Ofner, Cathrin Ritter, Selma Ugurel, Lorenzo Cerroni, Mathias Stiller, Thomas Bogenrieder, Flavio Solca, David Schrama, Jürgen Christian Becker · 2017 · Journal of Cancer Research and Clinical Oncology
29. Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy
    Ankita Sahu, P.K. Patra, Manoj Kumar Yadav, Meena Varma · 2017 · Journal of Receptors and Signal Transduction
30. ErbB4‐mediated regulation of vasculogenic mimicry capability in breast cancer cells
    Ryota Kawahara, Siro Simizu · 2021 · Cancer Science
31. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors
    Debroop Basu, Riya Pal, Maitrayee Sarkar, Soubhik Barma, Sumit Halder, Harekrishna Roy, Sisir Nandi, Asmita Samadder · 2023 · Current Topics in Medicinal Chemistry
32. Evaluation of the Effect of Fibroblasts on Melanoma Metastasis Using a Biomimetic Co-Culture Model
    Miaoben Wu, Enxing Yu, Kai Ye, Yuye Huang, Tiantian Ren, Mingjun Guo, Jun Yin, Kailei Xu, Peng Wei · 2023 · ACS Biomaterials Science & Engineering
33. Genomic and transcriptomic landscape to decipher the genetic basis of hyperpigmentation in Lanping black-boned sheep (Ovis aries)
    Yuqing Chong, Heli Xiong, Zhendong Gao, Ying Lu, Jieyun Hong, Jiao Wu, Xiaoming He, Dongmei Xi, Xiaolong Tu, Weidong Deng · 2024 · BMC Genomics
34. Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas
    Émerson Soares Veloso, Ivy Nayra Nascimento Gonçalves, Tatiany Luiza Silveira, Fernando Soares de Oliveira, Déborah Soares Vieira, Geovanni Dantas Cassali, Helen Lima Del Puerto, Enio F. Ferreira · 2020 · BMC Veterinary Research
35. Genetic variants in ERBB4 is associated with chronic hepatitis B virus infection
    Yao Liu, Qun Y. Zhou, Xiao‐Shun He, Li-Ming Song, Lin Chen, Weijuan Jiao, Tong Shen, Su Yao, Hua Wu, Zhi-Bin Hu et al. · 2015 · Oncotarget
36. Metastatic Syringocystadenocarcinoma Papilliferum: A Case Report, Tumor Genomic Profiling, and Literature Review
    Erdem Altunel, Aleksandr M. Perepletchikov, Olga N. Kozyreva · 2020 · Case Reports in Oncological Medicine
37. Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma
    Xiuyu Cai, Zhenghe Chen, Meiling Deng, Zhiyong Li, Qianchao Wu, Jinwang Wei, Chun Dai, Guan Wang, Chun Luo · 2020 · Annals of Translational Medicine
38. A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping
    Baptiste Louveau, Fanélie Jouenne, Pauline Tétu, Aurélie Sadoux, Aurélia Gruber, Eddie Lopes, Julie Delyon, Kévin Serror, Oren Marco, Laetitia Da Meda et al. · 2020 · Targeted Oncology
39. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells
    Guannan Zhu, Xiuli Yi, Sebastian Haferkamp, Sonja Hesbacher, Chunying Li, Matthias Goebeler, Tianwen Gao, Roland Houben, David Schrama · 2016 · Cancer Letters
40. Mutations in ERBB4 May Have a Minor Role in Melanoma Pathogenesis
    Antonella Manca, Amelia Lissia, Antonio Cossu, Corrado Rubino, Paolo A. Ascierto, Ignazio Stanganelli, Giuseppe Palmieri · 2013 · Journal of Investigative Dermatology
41. Prognostic Parameters for the Primary Care of Melanoma Patients: What Is Really Risky in Melanoma?
    Daniela Göppner, Martin Leverkus · 2011 · Journal of Skin Cancer
42. The EGFR/ERBB Receptor Family
    Fresia G. Pareja, Gur Pines, Yosef Yarden · 2015 · Springer eBooks
43. Higher Mutation Burden in High Proliferation Compartments of Heterogeneous Melanoma Tumors
    Tomasz M. Grzywa, Agnieszka Anna Koppolu, Wiktor Paskal, Klaudia Klicka, Małgorzata Rydzanicz, Jarosław Wejman, Rafał Płoski, Pawel Krzysztof Wlodarski · 2021 · International Journal of Molecular Sciences
44. Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients
    Takahiko Koyama, Kahn Rhrissorrakrai, Laxmi Parida · 2019 · BMC Cancer
45. The PI3K-AKT Pathway in Melanoma
    Alan E. Siroy, Michael A. Davies, Alexander J. Lazar · 2016 · Springer eBooks
46. Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation
    Ratna Dini Haryuni, Satoko Watabe, Asako Yamaguchi, Yayoi Fukushi, Tomohiro Tanaka, Yuki Kawasaki, Yue Zhou, Satoru Yokoyama, Hiroaki Sakurai · 2019 · Biochemical and Biophysical Research Communications
47. Characterizing mutation–expression network relationships in multiple cancers
    Shila Ghazanfar, Jean Yee Hwa Yang · 2016 · Computational Biology and Chemistry
48. Research Translation and Personalized Medicine
    James Brugarolas · 2012 · Springer eBooks
49. Rationale for Targeting the ErbB Family of Receptors in Patients with Advanced Squamous Cell Carcinoma of the Lung
    Peter Edward Hall, James F. Spicer, Sanjay Popat · 2015 · Future Oncology
50. Cutting Edge in Medical Management of Cutaneous Oncology
    Chong Ae Kim, ADIL I. DAUD, Susana Ortiz‐Urda, Sarah T. Arron · 2012 · Seminars in Cutaneous Medicine and Surgery
51. NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand
    Angela M. Jones, Peter M. Ferguson, Jacqui Gardner, Serena Rooker, T. Sutton, Antonio Ahn, Aniruddha Chatterjee, Vivienne M. Bickley, Makhdoom Sarwar, Patrick O. Emanuel et al. · 2016 · Oncotarget
52. ErbB4 as a Potential Molecular Target in the Treatment of Esophageal Squamous Cell Cancers
    Ke Zhao, Bao-Jun Chen, Zhiguo Chen · 2014 · The Scientific World JOURNAL
53. Network pharmacology‑based investigation of potential targets of triptonodiol acting on non-small-cell lung cancer
    Feng Jin, Xiaochen Ni, Shilong Yu, Xiaomin Jiang, Jun Ying Zhou, Defang Mao, Yanqing Liu, Feng Wu · 2023 · European journal of medical research
54. ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer
    Kari J. Kurppa, Matjaž Rokavec, Maria Sundvall, Pirkko‐Liisa Kellokumpu‐Lehtinen, Heikki Joensuu, Hiltrud B. Brauch, Klaus Elenius · 2014 · PLoS ONE
55. Genomic alterations in tumor tissue and ctDNA from Chinese pancreatic cancer patients.
    Anwen Xiong, Ning Ma, Guo Wei, Chunhua Li, Kainan Li, Bin Wang · 2021 · PubMed Central
56. The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation
    Woo Jung Sung, Dohyang Kim, Anlin Zhu, Namki Cho, Hee Min Yoo, Ji Heon Noh, Kyoung Mi Kim, Hyun‐Su Lee, Jaewoo Hong · 2022 · Frontiers in Pharmacology
57. Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
    Sarina Anne Piha-Paul, Chieh Tseng, Hai Thanh Tran, Aung Naing, Ecaterina E Ileana Dumbrava, DD Karp, Jordi Ahnert Rodon, Timothy Anthony Yap, Kanwal P. S. Raghav, Senthil Damodaran et al. · 2025 · ESMO Open
58. There is a world beyond protein mutations: the role of non‐coding RNA s in melanomagenesis
    Rolf Swoboda, Meenhard Herlyn · 2013 · Experimental Dermatology
59. A high-affinity ErbB4Fc fusion protein is a potent antagonist of heregulin-mediated receptor activation
    Eva J. Koziolek, Jacqueline F. Donoghue, John D. Bentley, George O. Lovrecz, Olan Dolezal, Colin Wesley Ward, Julie Rothacker, Edouard Collins Nice, Antony Wilks Burgess, Marc A. Hafner et al. · 2012 · Growth Factors
60. An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations
    Deepankar Chakroborty, Veera K. Ojala, Anna M. Knittle, Jasmin Drexler, Mahlet Z. Tamirat, Regina Ruzicka, Karin Bosch, Johanna Woertl, Susanne Schmittner, Laura L. Elo et al. · 2022 · Cancer Research Communications
61. The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China
    Qi-Ming Zhou, Wěi Li, Yuanxiang Guan, Xing Zhang, Xin-Chun Chen, Ya Ding, Xi-Zhi Wen, Rui-Qing Peng, Shumei Yan, Xiao-Shi Zhang · 2012 · 癌症：英文版
62. Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management
    Carman Ka Man Ip, Jun Yin, Patrick Kwok‐Shing Ng, Shiaw‐Yih Lin, Gordon Brent Mills · 2016 · AIMS Medical Science
63. Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
    Marika K.A. Koivu, Deepankar Chakroborty, Mahlet Z. Tamirat, Mark S. Johnson, Kari J. Kurppa, Klaus Elenius · 2020 · Molecular Cancer Therapeutics
64. The Eph Receptor Family
    Thomas N. Gaitanos, Irina Dudanova, Μαρία Σάκκου, Rüdiger Klein, Sónia Paixão · 2015 · Springer eBooks
65. The role of dual‐specificity phosphatase 3 in melanocytic oncogenesis
    Emmanouil Chousakos, Nikolaos Katsoulas, Nikolaos Kavantzas, Alexandros Stratigos, Andreas Ch Lazaris · 2022 · Experimental Dermatology
66. Identification of genetic modifiers of murine hepatic β-glucocerebrosidase activity
    Anyelo Durán, Boris Rebolledo‐Jaramillo, Valeria Olguín, Marcelo Rojas-Herrera, Macarena Las Heras, Juan F. Calderón, Silvana Zanlungo, David A. Priestman, Frances M. Platt, Andrés D. Klein · 2021 · Biochemistry and Biophysics Reports
67. Targeted Therapies in Melanoma
    Daniele Fanale, Giuseppe Bronte, Antonio Dello Russo · 2015 · Current clinical pathology
68. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures
    Soraya Curiel‐Olmo, Almudena García‐Castaño, Rebeca Vidal, Helena Pisonero, Ignacio Varela, Alicia León‐Castillo, E. Moya Trillo, Carmen González‐Vela, Nuria García‐Díaz, Carmen Almaráz et al. · 2015 · Oncotarget
69. New combinational therapies for cancer using modern statistical mechanics
    Jorge A. González, M. Acanda, Zubair Akhtar, David M Andrews, Jose Ignacio Azqueta, Eleanor M. Bass, A. Bellorín, Juan Pablo Couso, Mónica A. García-Ñustes, Yanelys Cabrera Infante et al. · 2019 · arXiv (Cornell University)
70. Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials
    Shilpa Bhatia, Luni Emdad, Swadesh Kumar Das, Hossein A. Hamed, Paul Dent, Devanand Sarkar, Paul B. Fisher · 2014 · Expert Opinion on Investigational Drugs
71. New developments in dermatological oncogenetics
    Manfred Kunz · 2013 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
72. A Network-Centric Framework for the Evaluation of Mutual Exclusivity Tests on Cancer Drivers
    Rafsan Ahmed, Cesim Erten, Aissa Houdjedj, Hilal Kazan, Cansu Yalçın · 2021 · Frontiers in Genetics
73. New Molecular Targets for the Systemic Therapy of Melanoma
    Kausar Begam Riaz Ahmed, A. Michael · 2011 · InTech eBooks
74. Mutation spectrum of the first melanoma genome points finger firmly at ultraviolet light as the primary carcinogen
    Nicholas K. Hayward · 2010 · Pigment Cell & Melanoma Research
75. It’s all in for the HER family in tumorigenesis
    Major Kenneth Lee IV, Anupama Sharma, Brian J. Czerniecki · 2009 · Expert Review of Vaccines
76. Melanoma: From Tumor-Specific Mutations to a New Molecular Taxonomy and Innovative Therapeutics
    Crystal A. Tonnessen-Murray, Nikolas K. Haass · 2015 · Springer eBooks
77. ERBB4 Drives the Proliferation of BRAF-WT Melanoma Cell Lines
    Lauren M. Lucas, Richard Lee Cullum, Joelle N. Woggerman, Vipasha Dwivedi, Jessica A. Markham, Connor M. Kelley, Elizabeth L. Knerr, Laura J. Cook, Howard C. Lucas, Damien S. Waits et al. · 2022 · medRxiv
78. Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies
    Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto-Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Khani Farahani, Deepankar Chakroborty, Nikol Dibus et al. · 2025 · Molecular Oncology
79. Genomics of Primary and Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis
    Mạnh Đức Hoàng, Thi Oanh Bui, Tu Van Dao, Van Quang Le, Célèste Lebbé, Guilhem Bousquet · 2026 · American Journal of Clinical Dermatology
80. The significance of quinazoline derivatives as potential multi-target anti-cancer agents: review article
    Mostafa A. Mansour, Samar H. Abbas, Asmaa M. AboulMagd, Hamdy Mohamed Abdel-Rahman, Mohamed Sayed Ali Osman · 2023 · Journal of advanced Biomedical and Pharmaceutical Sciences
81. EGFs and ERBBs—Brief history and prospects
    David F. Stern · 2010 · Seminars in Cell and Developmental Biology
82. Molecular Genetics of Melanoma Progression
    Jaskaren S. Kohli, Dorothy C. Bennett · 2017 · Encyclopedia of Life Sciences
83. New horizons in melanoma treatment: targeting molecular pathways.
    Christopher W. M. Soon, Alain Patrick Algazi, Edward N Cha, ADIL I. DAUD · 2010 · PubMed Central
84. Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy
    Rachel A. O’Keefe, Jennifer Rubin Grandis, Daniel E. Johnson · 2018 · Elsevier eBooks
85. Neuregulin Signaling in the Tumor Microenvironment
    Ruxue Jia, Hu Zhao, Shuiliang Wang · 2020 · Advances in experimental medicine and biology
86. Melanoma Genetics and Genomics
    Allen Ho, Goran B Jönsson, Hensin Tsao · 2017 · Springer eBooks
87. IdentifyingBRAFandKITmutations in melanoma
    Minoru Takata · 2013 · Expert Review of Dermatology
88. Multiscale modeling of the ErbB receptor tyrosine kinase signaling network through theory and experiment
    Shannon Telesco · 2011 · ScholarlyCommons (University of Pennsylvania)
89. Characterising Somatic Mutations in Cancer Genome by Means of Next‐generation Sequencing
    Mei Ling Chong, Chee‐Seng Ku, Mengchu Wu, Richie Chuan Teck Soong · 2012 · Encyclopedia of Life Sciences
90. Whole Genome Resequencing and 1000 Genomes Project
    Chee‐Seng Ku, Loy En Yun, Yudi Pawitan Y, Chia Kee‐Seng · 2010 · Wiley eBooks
91. Research on Rare Variants for Complex Diseases
    Chee‐Seng Ku, Patrik K. E. Magnusson, Kee Seng Chia, Yudi Pawitan Y · 2010 · Wiley eBooks
92. The identification of therapeutic targets in metastatic melanoma
    Ken Dutton‐Regester · 2012 · Faculty of Health
93. Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation
    Raphael Trenker, Devan C. Diwanji, Tanner Bingham, Kliment A. Verba, Natalia Jura · 2023 · eLife
94. Expression and prognostic value of LRIG1 and the EGF-receptor family in renal cell and prostate cancer
    Marcus Thomasson · 2009 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
95. Moving Forward: Making BRAF-Targeted Therapy Better
    Keith T. Flaherty · 2014 · Cancer drug discovery and develogment/Cancer drug discovery and development
96. Signaling Networks that Induce Melanomagenesis and Metastasis that can be Exploited for Therapeutic Benefit
    Eden Elizabeth Tanzosh · 2013
97. Targeted Molecular Therapy for Patients with Ovarian Cancer
    Samir A. Farghaly · 2013 · Springer eBooks
98. Biology of Melanoma
    Ruifeng Ray Guo · 2014 · Wiley eBooks
99. New research advances for treating metastatic melanoma
    Ettore Minutilli · 2010 · International Journal of Dermatology
100. Preclinical Study of PI3K and BRAF Inhibitors in Malignant Melanoma
     Marta López‐Fauqued · 2010 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)